Jennifer Spratlin, MD FRCPC
Alberta Health services · Cross Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jennifer Spratlin, MD FRCPC as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:48 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03469011 · A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.AHS Cancer Control Alberta · terminated · Papillary Thyroid Cancer · principal investigator
- Ph2NCT02632305 · A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract CancerAHS Cancer Control Alberta · active not recruiting · Unresectable Biliary Tract Cancer · principal investigator
- N/ANCT01411072 · Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas CancerAHS Cancer Control Alberta · unknown · Pancreas Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.